ePoster 

Die hochgeladenen ePoster sind nur für eingeloggte Teilnehmer ersichtlich. 

Bitte loggen Sie sich ein, um zu den ePoster zu gelangen. 

Hier geht es zum Log- in

 

Detaillierte Beitrags-Information

Zurück zur Liste

Beitragstitel 36-Month Outcomes of Combined Ab Interno Viscocanaloplasty (ABiC) in the Surgical Treatment of Open-Angle Glaucoma
Beitragscode P09
Autor:innen
  1. Kevin Gillmann Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom Präsentierende:r
  2. Amr Aref Clinique de l'Oeil, Onex
  3. Laëtitia Jessy Niegowski Clinique de l'Oeil, Onex
  4. Jean-Marc Baumgartner Clinique de l'Oeil, Onex
Präsentationsform ePoster
Themengebiete
  • Glaucoma
Abstract-Text Introduction: Ab interno viscocanaloplasty (ABiC) derives from ab externo viscocanalostomy and involves the catheterization of Schlemm’s canal with a flexible microcatheter through which viscoelastic material is injected to dilate the canal and its surrounding structures on 360°.The aim of this study was to analyze the safety profile and efficacy of ABiC through to 36 months post-operatively.
Methods: In this retrospective study carried out at a tertiary ophthalmology centre, all patients who underwent ABiC between January 2016 and January 2017 were retrospectively enrolled, and their medical records were analysed. Complete success was defined as a 36-month reduction in intraocular pressure (IOP) ≥ 20% from baseline with no concomitant medications. Qualified success criteria were identical, with no more medications than at baseline. When longer follow-up periods were available, mean IOP and medications were reported at the last visit.
Results: In all, 30 eyes of 25 patients were analysed, with a mean follow-up time of 42.3 ± 4.6 months. Mean IOP decreased from 25.9 ± 9.2 mmHg preoperatively to 13.8 ± 4.0 mmHg (-46.7%; p < 0.001) at the last visit. Concomitantly, the number of medications dropped from 3.4 ± 0.9 to 1.0 ± 1.2 (-70.6%; p < 0.001). Complete success at 36 months was achieved in 20% of eyes, and qualified success in 53%. Amongst eyes with a baseline MD < -9 dBs, 20% and 100% achieved complete and qualified success, respectively, and 66.7% of eyes that had previously undergone filtering surgery achieved both complete and qualified success, with a mean 3-year IOP of 10.7 ± 3.2 mmHg. A total of 14 eyes (46.7%) were considered surgical failure due to uncontrolled IOP, 8 of which (26.7%) required further filtering surgery. Sixteen adverse events were observed during the follow-up period, with IOP spikes > 30 mmHg during the first post-operative week being the most common complication (36.7%).
Conclusions: ABIC achieved a statistically significant reduction in IOP and anti-glaucoma medications through 3 years of follow-up, with a favourable safety profile. It may be a valid technique to allow long-term control of IOP in mild-to-severe open-angle glaucoma, including after failed filtering surgery.